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Abstract
Background: The primary objective of this study was to assess whether Zhengtian Capsule was non-inferior to
flunarizine in efficacy and safety profile for prevention of migraine in adults.
Methods: This was a double-dummy, double-blind, multicenter, positive drug (flunarizine), parallel randomized
controlled, non-inferior clinical trial. Patients (n = 360) were randomized in a 1:1 to receive either Zhengtian Capsule
or flunarizine, including 12 weeks’ intervention and 4 weeks’ follow-up. The primary outcome measure was
responder rate (defined as the percentage of subjects in a treatment group with 50 % or greater reduction in attack
frequency during treatment compared with the baseline period). The secondary outcome measures included
migraine attack frequency, the number of migraine days, pain evaluated by visual analogue scale (VAS) score,
duration of migraine attacks, the times of using analgesics, patient-reported outcome (PRO) measure of migraine
and the scores of short-form 36 Health Survey Scale (SF-36). Weight variation in both groups was also evaluated.
Adverse events were monitored throughout the trial.
Results: Zhengtian Capsule was non-inferior to flunarizine in responder rate at week 12 and follow-up period
(P = 0.002, P < 0.001). There was fewer migraine days in Zhengtian Capsule group at follow-up period compared
with flunarizine (P = 0.001). For the total duration of migraine attacks, there was significant group difference at week
4 which favored the control group (P = 0.009). For the total score of PRO scale, there was statistical difference
between the two groups at follow-up period (P = 0.021). There were also group differences between the two
groups in the dimensions of somatization symptoms at week 4 (P = 0.022) and functional status at week 12 and
follow-up period (P < 0.001, P < 0.001). However, there were no significant differences between the two groups in
migraine attack frequency, VAS scores reduction, consumption of acute pain drugs and the dimension scores of
SF-36 at any time interval of the treatment period (P > 0.05). No severe adverse events occurred in the trial.
Flunarizine was found associated with a weight gain.
Conclusion: Zhengtian Capsule was non-inferior to flunarizine with regard to the primary endpoint. In addition, it
could reduce migraine days and improve the functional status and somatization symptoms of migraine patients
with good safety profile.
Trial registration: This trial was registered at Chinese Clinical Trial Register (ChiCTR), ChiCTR-TRC-13004412.
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Background
Migraine is a common disabling primary headache
disorder characterized by recurrent unilateral location,
throbbing quality, moderate or severe intensity, associ-
ated with symptoms such as nausea, vomiting, photo-
phobia and phonophobia, usually aggravated by routine
physical activities [1]. According to the Global Burden of
Disease Survey 2010 (GBD2010), migraine was estimated
a global prevalence of 14.7 %, ranked as third most com-
mon diseases in the world in both males and females [2].
Generally, it has been reported that female migraine suf-
ferers tend to outnumber male sufferers by nearly 3 to 1
[3–5]. Migraine is burdensome and costly. On account
of substantial impairment on work or school productiv-
ity, it negatively impacts human capital accumulation
and brings about a heavy socioeconomic burden [6–8].
Migraine is also a disease that contributes to major
disability thus leading to low life quality. It was ranked
as the seventh-highest specific cause of disability world-
wide [2, 9]. In addition, it is associated with a number of
comorbidities, including psychiatric disease, sleep distur-
bances, stroke and other chronic pain disorders [10–12].
The status quo in China is similar to the world average
[13, 14]. Due to its high prevalence and disabling feature,
migraine has become an important target issue for
public health interventions.
Migraine is divided into acute episode and chronic
remission period. Accordingly, the treatment is divided
into abortive treatment and preventive treatment. The
former intends to return the patient to full function
within 2 h, whereas, the latter with a goal of improving
the health-related quality of life in patients with migraine.
For acute treatment, there are specific and nonspecific
treatment methods. Triptans and dihydroergotamine
are effective specific medications, nonsteroidal anti-
inflammatory drugs, opioids and barbitals are effective
nonspecific medications [15]. For the preventive treat-
ment, there are angiotensin receptor blockers (ARB),
angiotensin converting enzyme inhibitors (ACEI), antiepi-
leptic drugs (AEDs), antidepressant drugs, calcium chan-
nel blockers (CCB), beta-receptor blocker, etc. However,
there exists some side effects which inhibit the widely use
of these drugs [16, 17]. In this trial we use flunarizine as
the positive comparator drug because it is widely used for
migraine with proven efficacy and safety. Zhengtian
Capsule is a dosage form modified from Zhengtian Pill,
which is a Chinese Patent medicine proved effectively in
treating migraine in previous studies [18, 19]. It is
composed of 15 herbal compositions: Uncariae Ramulus
Cum Uncis(Gou Teng), Ephedrae Herba(Ma Huang),
Asari Radix Et Rhizoma(Xi Xin), Aconiti Lateralis
Radix Praeparata(Fu Pian), Paeoniae Radix Alba(Bai
Shao), Persicae Semen(Tao Ren), Cartham Flos(Hong
Hua), Rehmanniae Radix(Di Huang), Angelicae Sinensis
Radix(Dang Gui), Chuanxiong Rhizoma(Chuanxiong),
Notopterygh Rhizoma et Radix(Qiang Huo), Angelicae
Pubescentis Radix(Du Huo), Saposhnikoviae Radix(-
Fang Feng), Spatholobi Caulus(Ji Xue Teng), Angelicae
Dahuricae Radix(Bai Zhi). Studies on Zhengtian Capsule
with a multicenter, double blind, randomized controlled
trial are rarely known. Hence, we conducted a multi-
center, double-blind, double-dummy, randomized con-
trolled, non-inferior clinical trial to determine whether or
not Zhengtian Capsule was non-inferior in effectiveness
and safety to flunarizine in the prophylaxis of migraine.
Methods
Study design
A multicenter, prospective, double-blind, double-dummy,
positive drug parallel controlled, non-inferior clinical trial
was conducted in our study. The study was carried out on
360 patients with migraine in 13 participating centers
simultaneously. Since Zhengtian Capsule was previously
reported rarely, the sample calculation of the study was
determined in reference of Zhengtian Pill. The previous
study showed that the responder rate of migraine attacks
was 63.3 % in Zhengtian Pill and 52 % in flunarizine. We
designed a non-inferiority testing. The sample size was
estimated using standard methods for test of non-
inferiority. Non-inferiority margin is - 5 %, alpha = 0.05,
beta = 0.10. The computational formula was as follows:
n ¼ z1−α þ z1−β
 2  P1 1−P1ð Þ þ P2 1−P2ð Þ½ 
ε−δð Þ2
¼ 1:65þ 1:28ð Þ
2  0:63 1−0:63ð Þ þ 0:52 1−0:52ð Þ½ 
0:113− −0:05ð Þð Þ2
≈156
To allow for a maximum drop-out rate of up to 15 %,
360 individuals should be enrolled in this study. We
allocated a proportion of the two groups (1:1) and de-
termined 180 patients for each group. There were a
3-month well documented retrospective history and a
run-in period of 4 weeks without treatment. Then
migraineurs who met the inclusion criteria were assigned
to the experimental group and the control group
randomly. The experimental group were treated with
Zhengtian Capsule (0.9 g, three times a day) and flunari-
zine simulation (5 mg, quaque nocte). The control group
were treated with flunarizine (5 mg, q.n) and Zhengtian
Capsule simulation (0.9 g, tid). All the participants then
underwent a therapeutic course of 12-week and 4-week of
follow-up. There were totally five visits for each eligible
patient conducted every 4-week interval: At baseline, week
4, week 8, week 12 and follow-up period respectively.
Ibuprofen and other analgesic drugs were permitted dur-
ing the process if necessary which were recorded in detail.
Headache diary was handed out to each included patient,
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they were instructed to note the characteristics of the
migraine attacks such as headache severity, functional
disability, associated symptoms such as nausea, vomiting,
photophobia, and phonophobia. The protocol and in-
formed consent were reviewed and approved by the Ethics
Committee of the Affiliated Dongzhimen Hospital of
Beijing University of Chinese Medicine before commen-
cing the trial. This study protocol was in accordance with
the Declaration of Helsinki and Good Clinical Practice
(GCP) ethical guidelines. Written informed consent was
obtained from each subject prior to participation. The
randomization sequence was computer generated in a 1:1
ratio by an independent statistician using SAS statistical
software. There were accordant drug codes. All of the trial
drugs were dispensed sequentially by a specified drug
administrator in a separate reception room according to
the sequence of inclusion of eligible patients. There were
also sealed envelopes which served as emergency enve-
lopes, when there were severe adverse events investigators
would know which drug patients had received. All
researchers, participants and statisticians were masked to
treatment allocation throughout the trial.
Setting and participants
Patients were recruited through advertising and out-
patient departments of the 13 participating hospitals
across China and through advertising. Four hundred
eighteen patients were screened and 360 patients were
randomized to treatment. The assessment was per-
formed by principle investigators of the participating
hospitals. The 13 participating hospitals were as follows:
Dongzhimen Hospital affiliated to Beijing University of
Chinese Medicine, Xiamen Hospital of Traditional
Chinese Medicine, the First Subsidiary Hospital of Anhui
College of Traditional Chinese Medicine, the Affiliated
Hospital to Changchun University of Chinese Medicine,
the Central Hospital of Xuhui District, Hubei Hospital
of Traditional Chinese Medicine, Nanfang Hospital of
Southern Medical University, Beijing Pinggu District
Hospital of Traditional Chinese Medicine, the Second
Hospital of Jilin University, the First Affiliated Hospital
of Henan University of Traditional Chinese Medicine,
the Xiangya Hospital Central South University, the First
Affiliated Hospital of Chongqing University of Traditional
Chinese Medicine, Zhejiang Hospital of Traditional
Chinese Medicine. All the patients had blood routine,
urine routine, liver and renal function tests, electrocardio-
gram examinations, myocardial enzyme, myocardial injury
markers, CT or MRI to exclude severe accompanying
conditions before entrance to the trial.
Diagnostic criteria
Migraine without aura (MO) or with a typical aura (MA)
both fulfilled the second edition of International
Classification of Headache Disorders (ICHD-II) diagnos-
tic criteria for migraine strictly [20].
Inclusion criteria
A subject would be eligible for inclusion in the trial
only if all the following criteria were fulfilled at base-
line: (1) Diagnosed as MO or MA according to the
diagnostic criteria specified by ICHD-II [20]. (2) Age
of first onset ≤ 50 years old. (3) The patients had at
least a 12-month history of migraine with or without
aura as defined by the criteria of the 2004 Inter-
national Headache Society. (4) Average migraine at-
tacks per month were between 2 and 6 (including
two times and six times) at baseline period. (5) Age
between 18 and 65 years old.
Exclusion criteria
A subject would not be eligible for inclusion in the trial
if any of the following criteria applied at baseline: (1)
Analgesics were used for acute headache >10 times per
month. (2) For the previous 3 months before inclusion,
migraine prevention drugs was taken, such as beta
blockers, calcium channel blockers, anti-epileptic drugs,
antidepressants and 5-HT receptor blockers, etc. (3)
Alcohol or other drug abusers. (4) Combined with severe
primary diseases such as cardiovascular, cerebrovascular,
liver, kidney, hematopoietic system disease, etc. (5)
Psychiatric patients. (6) Allergic to the trial drugs. (7)
Pregnancy and lactation.
Interventions
Participants in the experimental group were given
Zhengtian Capsule and flunarizine simulation, while the
control group were given flunarizine and Zhengtian
Capsule simulation. The active drugs and simulations
had identical appearance and were indistinguishable in
taste, color, appearance and smell. Both of them were
issued in a sealed box and provided by Hua Run San-Jiu
Pharmaceutical Co.LTD. Zhengtian Capsule was taken
0.9 g at a time, three times a day after meal while flunar-
izine was taken 5 mg, quaque nocte. Ibuprofen and
other analgesic drugs were permitted to use when neces-
sary and should be well recorded. With other diseases
such as infection, hypertension and diabetes, concomi-
tant therapies that were allowed or on a restricted basis
should be specified.
Outcome measures
The primary outcome measure was responder rate
(defined as the percentage of subjects in a treatment
group with 50 % or greater reduction in attack frequency
during treatment compared with the baseline period)
[21]. Migraine attack temporarily relieved due to sleep
or treatment relapsed within 48 h was defined as one
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single attack. Forty-eight hours of freedom between
attacks of migraine permits identification of individual
attacks.
The secondary outcome measures were migraine
attack frequency, the number of migraine days, intensity
for pain evaluated by VAS score, duration of migraine
attacks, the times of using analgesics, PRO sacle of
migraine and the SF-36 questionnaire. Weight changes
were also measured. The VAS is a 10 cm continuous
horizontal line that measures the severity of headache, it
is a quantitative index for pain. Make the patients point
out the number that can mostly represent the pain of
his headache. Zero stands for no headache, ten stands
for extreme headache. Score range 0 ∼ 4 stands for mild
headache, score range 4 ∼ 7 stands for moderate head-
ache, score range 7 ∼ 10 stands for severe headache [22].
The duration of each attack refers to the time from
migraine onset to vanish, if the patient goes to sleep in
pain, the time of vanishing is when he wakes up. Patient
reported outcome (PRO) is a modern scientific approach
widely used in evaluating outcomes of clinical trials
based on patient centred evidence [23–25]. A PRO is
defined as any report of the status of a patient’s health
condition that comes directly from the patient, without in-
terpretation of the patient’s response by a clinician or any-
one else [26]. It highlights the importance of assessing the
effectiveness of health care from the patients’ perspective.
Since there was no PRO sacle validated for migraine
patients. Our previous study established a PRO sacle
for remission period migraine patients with compre-
hensive contents and reasonable structure [27]. The
four domains are headache, somatization symptoms,
psychological state and functional status. It has been
proved to imply treatment effect from multiple dimen-
sions and with good reliability, validity and reaction
degree [28, 29]. The PRO sacle also has a good conno-
tation of traditional Chinese medicine with the concept
of the holism of body and spirit as one of the basic
Chinese medical theories. It has become a good com-
plement to migraine clinical efficacy evaluation system
and should not be ignored.
The SF-36 questionnaire assesses Health Related
Quality Of Life in eight domains: Mental Health (MH),
Role Emotional (RE), Social Functioning (SF), Vitality
(VT), General Health (GH), Body Pain (BP), Role Phys-
ical (RP), Physical Functioning (PF). There are also two
scales for mental and physical health, Mental Compo-
nent Summary (MCS) score and Physical Component
Summary (PCS) score.
In addition, the blood routine, urine routine, liver and
kidney function tests, electrocardiogram, myocardial
enzyme and myocardial injury markers were evaluated at
the baseline and the treatment ended as safety evalu-
ation endpoints. During the study, all adverse events
were monitored and recorded on the case report form
(CRF) including time of onset and resolution, severity
and the relationship between adverse events and drugs
analyzed by investigators.
Statistical methods
SAS (Statistical package version 9.2) was used for
Statistical analysis, which were prespecified using both
per-protocol set (PPS) and full analysis set (FAS). PPS
analyses were based on data from patients who had good
compliance to complete the trial according to the
criteria of protocol and who had taken 80–120 %
amount of trial drugs. FAS analyses took the principle of
intention-to-treat which were based on data from all the
randomized patients who took at least one trial drug
and the last observation carried forward (LOCF)
approach was used to impute missing data. FAS is the
main analysis set in this trial.
In addition, responder rate was compared between the
two groups using non-inferior test, with non-inferiority
margin - 0.5. For the changes in migraine attack fre-
quency, the number of migraine days, duration of mi-
graine attacks, the times of using analgesics, VAS scores,
PRO scores, weight changes and SF-36 dimension scores,
analysis of covariance (ANCOVA) with baseline variables
as covariates were used to compare the differences
between the two groups at different time points. The level
of significance was set at 0.05, if P < 0.05, there were statis-
tical differences.
Results
Of all the 360 randomized patients, 357 of their data
were included in FAS analyses (intention-to-treat ana-
lyses). There were two lost to follow up and one with-
drew the informed consent in the treatment group.
Therefore, 177 of 180 patients in treatment group and
all patients in control group were included into FAS. In
comparison, 312 patients were put into PPS, 153 from
the treatment group and 159 from the control group. In
the process of the entire study, 48 patients dropped out,
a rate of 13.33 % (27 from the treatment group 15 %, 21
from the control group 11.67 %). Among these, 21
patients lost to follow-up (12 from the treatment group,
nine from the control group), four patients withdrew the
informed consent (three from the treatment group, one
from the control group), three patients dropped out for
adverse events (two from the treatment group, one from
the control group), 13 patients dropped out because of
overstepping the time window (eight from the treatment
group, five from the control group), seven dropped out
for other reasons. The reasons for the dropouts are
detailed in Fig. 1.
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Characteristics of demography and baseline
The demographic and baseline clinical characteristics of
the two groups were comparable at baseline as shown in
Table 1. There were no statistical significances in FAS
between the two groups (P > 0.05).
Responder rate
The responder rates in the treatment group and
control group were 21.47 % VS 21.11 % after 4 weeks
(P = 0.108), 34.46 % VS 38.89 % after 8 weeks (P = 0.455),
59.89 % VS 49.44 % after 12 weeks (P = 0.002) and
54.80 % VS 38.33 % at follow-up period (P < 0.001).
After 12 weeks’ treatment and during follow-up
period, Zhengtian Capsule was non-inferior to flunari-
zine (Table 2).
Migraine attacks
Migraine attacks have significantly decreased in the
treatment group from 3.37 ± 1.16 at baseline to 1.37 ±
1.30 during follow-up period, whereas from 3.53 ± 1.11
to 1.55 ± 1.30 in the control group. However, no group
differences were seen at any time points (Table 3).
Number of migraine days
As compared to baseline, migraine days decreased
throughout the study period in both groups. The dif-
ference in the number of migraine days between the two
groups was significant at follow-up period (P = 0.001)
(Table 3).
VAS scores
After treatment, the VAS scores in the two groups de-
clined month by month compared with the baseline.
During the treatment course, the VAS scores decreased
from 5.63 ± 1.31 to 3.87 ± 1.25 throughout the study
period in the treatment group, whereas from 5.63 ± 1.27
to 3.85 ± 1.41 in the control group. However, there were
no statistical differences between the two groups at any
4-week of time interval (Table 3).
Total duration of migraine attacks
There was a significant decrease in total duration of
migraine attacks per 4 weeks in both groups, and there
was significant group difference at week 4 which favored
the control group (P = 0.009) (Table 3).
Analgesic consumption
In both groups, frequency of using acute pain drugs at
each time point was markedly reduced compared to
baseline. However, there were no significant differences
between the two groups at week 4, week 8, week 12 and
follow-up period (P > 0.05) (Table 3).
The scores of patient reported outcome (PRO) scale of
migraine
During the study period, the total scores of PRO
were descending gradually in both groups. At
follow-up period, there was statistical difference be-
tween the two groups (P = 0.021). For the dimension
Fig. 1 Flow diagram of the study progress about enrollment, randomization, intervention, and completion of the trial
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score of functional status, there were group differ-
ences between the two groups at week 12 and
follow-up period (P < 0.001, P < 0.001). For the di-
mension score of somatization symptoms, there was
group difference at week 4 after treatment (P = 0.022)
(Table 4).
SF-36
After 12 weeks’ treatment, most of the sub-dimensions
of the SF-36 scores have improved in both groups. How-
ever, no significant differences were observed between
the two groups (P > 0.05) (Table 5).
Weight changes
Notably, we found patients taking flunarizine had a
weight gain, whereas those taking Zhengtian Capsule
were not evident. A significant difference between the
two groups was observed in the change of weight
gain from baseline and week 8 (P < 0.001), week 12
(P < 0.001) (Table 6).
Safety and tolerability
In total, there were 46 (12.8 %) patients experienced
adverse events in the process of the trial, 21 (11.86 %)
from the treatment group, 25 (13.89 %) from the control
group (P = 0.636). The adverse events were drowsiness,
canker sore, upper respiratory tract infection, elevated
ALT, et al. There was no need of special clinical dispose.
No significant serious adverse events appeared in both
groups. In addition, the compliance was similar in two
groups and there was no statistical difference (P = 0.654).
Discussion
In the present randomized controlled trial, Zhengtian
Capsule and flunarizine were compared with respect to
effectiveness and safety profile. We have shown that
Table 1 Baseline characteristics of migraine patients (FAS)
Parameters Treatment group (n = 177) Control group (n = 180) P value
sex(Male/Female) 54/123 63/117 0.366
Age(year) 39.70 ± 12.81 38.99 ± 11.56 0.654
weight 59.74 ± 9.22 60.94 ± 10.07 0.301
Course (months) 95.76 ± 86.82 91.61 ± 81.87 0.695
Migraine days 4.02 ± 2.16 4.09 ± 1.73 0.181
Migraine attacks 3.37 ± 1.16 3.53 ± 1.11 0.099
Total duration(h) 31.87 ± 36.47 30.26 ± 27.90 0.936
VAS scores 5.63 ± 1.31 5.63 ± 1.27 0.661
Analgesic consumption(times) 1.34 ± 1.66 1.35 ± 1.87 0.726
Total scores of PRO 34.34 ± 5.82 34.94 ± 5.63 0.189
Headache 12.50 ± 1.983 12.71 ± 1.89 0.237
Somatization symptoms 10.53 ± 2.47 10.50 ± 2.51 0.910
Psychological state 4.71 ± 1.46 4.89 ± 1.49 0.195
Functional status 5.77 ± 1.51 5.92 ± 1.49 0.348
PF 92.91 ± 7.07 92.97 ± 8.08 0.527
RP 63.07 ± 37.51 64.56 ± 37.56 0.257
BP 53.71 ± 13.78 52.97 ± 13.98 0.636
GH 60.91 ± 16.93 61.86 ± 17.19 0.531
VT 72.52 ± 13.87 72.31 ± 14.71 0.781
SF 77.07 ± 13.18 75.24 ± 14.56 0.630
RE 70.42 ± 36.22 64.13 ± 39.73 0.371
MH 72.93 ± 14.41 71.39 ± 15.87 0.766
MCS 73.23 ± 14.83 70.77 ± 17.60 0.620
PCS 67.65 ± 14.31 68.09 ± 14.68 0.596
Table 2 Comparison of responder rate (FAS)





4 W 38(21.47 %) 38(21.11 %) 0.108
8 W 61(34.46 %) 70(38.89 %) 0.455
12 W 106(59.89 %) 89(49.44 %) 0.002*
Follow-up period 97(54.80 %) 69(38.33 %) <0.001*
Note: Non-inferiority margin was −0.5
*P < 0.05 for data comparison between groups after treatment
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Zhengtian Capsule was non-inferior to flunarizine in
responder rate at week 12 and follow-up period.
To our knowledge, this was the first active-controlled
randomized trial of Zhengtian Capsule on migraine
prevention which was consistent with Guidelines for
Controlled Trials of Drugs in Migraine (second edition)
[21]. In this trial, Zhengtian Capsule showed similar
efficacy and safety with flunarizine, which was being
recommended as a first-line drug for preventive treatment
of migraine by European Federation of Neurological
Societies (EFNS) [30].
Previous studies have shown that migraineurs accor-
dantly report a lower quality of life in physical health,
mental health, social functioning and academic perform-
ance compared with those non-migraineurs [31]. A large
percent of migraine patients were presented functional
symptoms [32] and associated somatic symptoms [33].
Negative affect is a common trigger of migraine which
plays an important role in the occurrence and development
of migraine [34]. In our trial, Zhengtian Capsule was found
to have a strength in improving patients’ functional status
and somatization symptoms thus improving the life quality
of migraineurs.
Although there was no significant difference between
the two groups regarding the incidence of adverse events
in the current study and no severe adverse events
occurred, there was unfavorable gained weight in the
flunarizine group in our findings. This result was in
agreement with the findings of previous trials by
Sørensen PS [35], Luo N [36] and Wang LP [37].
Zhengtian Capsule, on the other hand, was not signifi-
cantly affect body weight, complete blood count, or liver
and kidney functions which suggested that this herbal
drug is safe to use. Although the results of the present
study need to be confirmed in future larger clinical trials,
Zhengtian Capsule holds promising potential as an effect-
ive and practical means to prevent migraine.
The strengths of our study lies in the following
aspects. Firstly, the sample size was large and patients’
selection biases were avoided with the randomization
and blinding method. Secondly, in view of ethic we
included an active control group instead of placebo
Table 3 Differences from baseline in efficacy variables at different time points (FAS)
Variable Treatment group (n = 177) Control group (n = 180) P value
Migraine attacks
4 W 2.66 ± 1.40 2.66 ± 1.20 0.864
8 W 2.04 ± 1.30 1.93 ± 1.19 0.153
12 W 1.57 ± 1.46 1.42 ± 1.12 0.460
Follow-up period 1.37 ± 1.30 1.55 ± 1.30 0.398
Migraine days
4w 2.98 ± 1.74 2.91 ± 1.41 0.994
8w 2.25 ± 1.72 2.13 ± 1.42 0.588
12 w 1.73 ± 1.78 1.58 ± 1.34 0.093
Follow-up period 1.46 ± 1.55 1.68 ± 1.50 0.001*
VAS scores
4w 4.94 ± 1.26 4.79 ± 1.14 0.990
8w 4.34 ± 1.31 4.22 ± 1.23 0.404
12 w 3.58 ± 1.05 3.26 ± 1.47 0.141
Follow-up period 3.87 ± 1.25 3.85 ± 1.41 0.852
Total Duration(h)
4w 19.70 ± 19.69 19.18 ± 19.24 0.009*
8w 14.68 ± 21.83 12.41 ± 14.41 0.753
12 w 11.71 ± 24.83 8.69 ± 12.89 0.526
Follow-up period 7.55 ± 13.76 7.31 ± 11.74 0.140
Analgesic consumption (times)
4w 0.96 ± 1.30 1.01 ± 1.59 0.229
8w 0.86 ± 1.65 0.76 ± 1.42 0.862
12w 0.70 ± 1.52 0.51 ± 1.07 0.360
Follow-up period 0.51 ± 1.37 0.41 ± 1.29 0.652
Note: *P < 0.05 for data comparison between groups after treatment
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control. Additionally, the design was consistent with
Guidelines for Controlled Trials of Drugs in Migraine
(second edition) and the outcome measures we used
were reliable. Nevertheless, the present study has some
limitations that warrant consideration. Most of the out-
come measures used in our trial were based on patient’s
subjective feelings and there weren’t many objective
indicators. Besides, a daily dose of 5 mg flunarizine was
a relatively low dose compared with the previous studies
[38, 39] which may have led to a modest improvement
in the efficacy outcome measures of migraine. Ten milli-
gram flunarizine may guarantee a more rapid efficacy
[40]. Therefore, we should bear these in mind when
interpreting our findings.
Conclusion
In summary, Zhengtian Capsule was non-inferior to flu-
narizine with regard to the primary endpoint. In addition,
Table 4 Comparison of the scores of PRO for migraine (FAS)
Treatment group (n = 177) Control group (n = 180) P values
Total score
4w 29.68 ± 5.87 30.18 ± 5.86 0.767
8w 26.97 ± 6.72 26.79 ± 7.26 0.455
12 w 22.90 ± 6.63 23.80 ± 7.27 0.301
Follow-up period 21.61 ± 6.47 23.41 ± 6.80 0.021*
Headache
4w 10.88 ± 2.07 11.05 ± 2.24 0.725
8w 9.56 ± 2.62 9.52 ± 2.76 0.643
12 w 8.54 ± 2.78 8.23 ± 2.88 0.246
Follow-up period 7.95 ± 2.73 8.31 ± 2.98 0.283
Somatization symptoms
4w 9.46 ± 2.66 9.48 ± 2.48 0.022*
8w 8.83 ± 2.67 8.57 ± 2.72 0.340
12 w 7.62 ± 2.51 7.72 ± 2.65 0.660
Follow-up period 7.52 ± 2.49 7.61 ± 2.38 0.745
Psychological state
4w 4.26 ± 1.36 4.43 ± 1.45 0.650
8w 3.97 ± 1.36 4.14 ± 1.56 0.565
12w 3.51 ± 1.29 3.81 ± 1.39 0.086
Follow-up period 3.42 ± 1.24 3.72 ± 1.29 0.101
Functional status
4w 5.08 ± 1.41 5.22 ± 1.52 0.697
8w 4.61 ± 1.58 4.55 ± 1.63 0.442
12 w 3.23 ± 1.36 4.04 ± 1.59 P < 0.001*
Follow-up period 2.71 ± 1.16 3.77 ± 1.46 P < 0.001*
*P < 0.05 for data comparison between groups aftertreatment
Table 5 Comparison of the dimension scores of SF-36 (FAS)
Dimension Treatment group Control group P value
PF 92.99 ± 9.96 93.972 ± 9.18 0.268
RP 74.00 ± 34.36 74.44 ± 34.75 0.648
BP 71.85 ± 16.90 73.87 ± 17.17 0.171
GH 67.55 ± 15.71 66.70 ± 16.54 0.381
VT 75.96 ± 13.80 76.03 ± 14.48 0.892
SF 81.85 ± 14.59 83.40 ± 15.17 0.127
RE 78.72 ± 35.07 81.29 ± 32.52 0.174
MH 75.66 ± 13.54 74.24 ± 14.39 0.407
MCS 78.05 ± 16.18 78.74 ± 16.02 0.299
PCS 78.57 ± 13.61 78.03 ± 15.12 0.594






4w 59.88 ± 9.17 61.15 ± 10.01 0.290
8w 59.89 ± 9.13 61.51 ± 9.99 P < 0.001
12 w 60.27 ± 9.08 61.97 ± 10.00 P < 0.001
Follow-up period 60.31 ± 9.05 61.46 ± 10.07 0.871
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it could reduce migraine days and improve the functional
status and somatization symptoms of migraine patients
with good safety profile. This Chinese Patent Medicine
may therefore be an option for the prophylactic treatment
of migraine.
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